【摘要】：目的：本項(xiàng)目旨在通過前列腺指數(shù)、凋亡抑制基因Bcl-2、凋亡促進(jìn)基因Bax來研究補(bǔ)腎活血通淋方治療良性前列腺增生癥的作用機(jī)制，評(píng)價(jià)補(bǔ)腎活血通淋方對(duì)良性前列腺增生癥大鼠模型Bcl-2和Bax的影響，為中醫(yī)藥診治良性前列腺增生癥提供較為科學(xué)的理論和實(shí)驗(yàn)依據(jù)。 方法：雄性Wistar大鼠60只，編號(hào)稱重，隨機(jī)分為6組，每組10只，即假手術(shù)組、模型組、保列治組（陽性對(duì)照組）、補(bǔ)腎活血通淋方低劑量組、補(bǔ)腎活血通淋方中劑量組、補(bǔ)腎活血通淋方高劑量組。大鼠適應(yīng)性喂養(yǎng)1周后開始造模。各組均腹腔注射10％的水合氯醛（3.5mg/kg）麻醉，無菌操作下進(jìn)行手術(shù)，經(jīng)腹腔摘除雙側(cè)睪丸，假手術(shù)組僅麻醉后切開腹腔，游離并不摘除雙側(cè)睪丸。術(shù)后恢復(fù)7天，假手術(shù)組不注射丙酸睪酮，給予10ml/kg生理鹽水，余5組按造模方法（每只大鼠每天皮下注射丙酸睪酮5mg/kg）造模，造模開始后，模型組給予10ml/kg生理鹽水，保列治組給予0.8mg/kg，（溶于10ml生理鹽水，相當(dāng)于臨床用藥量的10倍），補(bǔ)腎活血通淋方低劑量組給予5ml/kg（相當(dāng)于臨床用藥量的5倍）、補(bǔ)腎活血通淋方中劑量組給予10ml/kg（相當(dāng)于臨床用藥量的10倍），補(bǔ)腎活血通淋方高劑量組給予15ml/kg（相當(dāng)于臨床用藥量的15倍）。以上均采用灌胃給藥，1天1次，每周稱體重1次，以調(diào)節(jié)給藥用量，連續(xù)30天。末次給藥24h后，，斷頭處死動(dòng)物，取前列腺組織，分組標(biāo)記，大鼠前列腺用電光分析天平稱重，獲取前列腺濕重，同時(shí)制作光鏡和免疫組化標(biāo)本，對(duì)各組標(biāo)本進(jìn)行分析并觀察光鏡下前列腺細(xì)胞形態(tài)變化。 結(jié)果：3個(gè)中藥治療組大鼠前列腺濕重、前列腺指數(shù)及Bcl-2表達(dá)水平均明顯低于模型組，且Bax的表達(dá)水平均明顯高于模型組，其中尤其以補(bǔ)腎活血通淋方高劑量組最為明顯。補(bǔ)腎活血通淋方高、中劑量組與保列治組比較有統(tǒng)計(jì)學(xué)意義；補(bǔ)腎活血通淋方低劑量組與保列治組比較時(shí)，Bcl-2表達(dá)水平有統(tǒng)計(jì)學(xué)意義，Bax表達(dá)水平無統(tǒng)計(jì)學(xué)意義。 模型組大鼠前列腺組織可見明顯的病理性改變，補(bǔ)腎活血通淋方低劑量組與保列治組大鼠前列腺組織的病理性改變較模型組減輕，補(bǔ)腎活血通淋方中劑量組大鼠前列腺組織的病理性改變較模型組減輕，補(bǔ)腎活血通淋方高劑量組大鼠前列腺組織的病理性改變較模型組顯著減輕，各組大鼠前列腺組織病理學(xué)改變均有統(tǒng)計(jì)學(xué)意義。
[Abstract]:Objective: to study the mechanism of Bushen Huoxue Tongling recipe (BXT) in the treatment of benign prostatic hyperplasia (BPH) by means of prostate index and apoptosis suppressor gene Bcl-2, apoptosis promoting gene Bax. To evaluate the effect of Bushen Huoxue Tongling recipe on Bcl-2 and Bax in rat model of benign prostatic hyperplasia, and to provide scientific theoretical and experimental basis for the diagnosis and treatment of benign prostatic hyperplasia by traditional Chinese medicine. Methods: sixty male Wistar rats were randomly divided into 6 groups with 10 rats in each group, namely sham operation group, model group, Baoliao group (positive control group), low dose group of Bushen Huoxue Tongling recipe and middle dose group of Bushen Huoxue Tongling recipe. High dose group of Bushen Huoxue Tongling prescription. The rats were fed adaptively for 1 week and the model was made. In each group, 10% chloral hydrate (3.5mg/kg) was injected intraperitoneally and operated under aseptic operation. Bilateral testes were removed through abdominal cavity. In sham operation group, abdominal cavity was cut only after anesthesia, and bilateral testes were not removed free. Seven days after the operation, no testosterone propionate was injected into the sham operation group and 10ml/kg saline was given. The remaining 5 groups were modeled by subcutaneous injection of testosterone propionate 5mg/kg per day in the remaining 5 groups. After the establishment of the model, the rats in the sham operation group were given normal saline. The model group was given 10ml/kg saline, the Paulie group was given 0.8mg / kg, (dissolved in 10ml saline, equivalent to 10 times the clinical dosage), and the low dose group of Bushen Huoxue Tongling recipe was given 5ml/kg (equivalent to 5 times the clinical dosage). The middle dose group of Bushen Huoxue Tongling recipe was given 10ml/kg (equivalent to 10 times of clinical dosage) and the high dose group of Bushen Huoxue Tongling recipe was given 15ml/kg (equivalent to 15 times of clinical dosage). All of them were administered intragastrically once a day and weighed once a week to regulate the dosage of the drug for 30 consecutive days. 24 hours after the last administration, the animals were killed by decapitation, the prostate tissue was taken and labeled in groups. The rat prostate was weighed by electro-light analysis balance, and the wet weight of the prostate was obtained. At the same time, the specimens of light microscope and immunohistochemistry were made. The morphological changes of prostate cells were observed under light microscope. Results: the wet weight of prostate, prostate index and expression of Bcl-2 in three groups were significantly lower than those in model group, and the expression level of Bax was significantly higher than that in model group, especially in the high dose group of Bushen Huoxue Tongling Formula. The expression level of Bcl-2 was statistically significant in the low dose group of Bushen Huoxuetongling recipe and the group of Baolizhi, but there was no statistical significance in the expression level of Bax in the low dose group of Bushen Huoxue Tongling recipe and in the group of Baolingzhi (P < 0.05). Obvious pathological changes were observed in the prostate tissue of the model group. The pathological changes of the prostate tissue in the low dose group of Bushen Huoxue Tongling recipe and Baolizhi group were less than those in the model group. The pathological changes of prostate tissue in the middle dose group of Bushen Huoxue Tongling recipe were less than those in the model group, and the pathological changes of the prostate tissue in the high dose group of Bushen Huoxue Tongling recipe were significantly less than those in the model group. The histopathological changes of prostate in each group were statistically significant.
【學(xué)位授予單位】：河南中醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R-332;R277.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 顧方六;我國良性前列腺增生和前列腺癌發(fā)病調(diào)查[J];北京醫(yī)科大學(xué)學(xué)報(bào);2000年01期

2 杜斌林;;杜天銀老中醫(yī)臨證治驗(yàn)舉隅[J];甘肅中醫(yī);2007年11期

3 方諾;左建嬌;;益氣活血清熱利濕方對(duì)大鼠前列腺增生模型PCNA、Bcl-2及Bax的影響[J];河北中醫(yī);2010年06期

4 夏玉存;前列復(fù)康系列沖劑治療前列腺增生病[J];湖北中醫(yī)雜志;2002年03期

5 陳暉,劉修恒,金化民;雌雄激素聯(lián)用制作犬前列腺增生動(dòng)物模型[J];臨床泌尿外科雜志;2005年01期

6 張熙;賀菊喬;劉麗芳;席建元;;良性前列腺增生的病因研究概況[J];中國民族民間醫(yī)藥;2010年07期

7 吳家清;雌激素及其受體在良性前列腺增生中的作用[J];中華男科學(xué);2002年03期

8 吳建輝,孫祖越,朱焰,鐘恩宏,何桂林,劉桂明;去勢(shì)Beagle犬前列腺增生模型的建立[J];中華男科學(xué);2003年06期

9 張春和,李曰慶;中醫(yī)藥治療良性前列腺增生的實(shí)驗(yàn)研究進(jìn)展[J];中華男科學(xué)雜志;2004年12期

10 郭凱;時(shí)丹;楊磊林;甑山林;任鐵華;;四黃前列片對(duì)尿生殖竇植入法小鼠前列腺增生模型的影響[J];中國男科學(xué)雜志;2005年06期

本文編號(hào)：2446037